

Award Number: DAMD17-02-1-0498

TITLE: Investigation of Lobular Carcinoma In Situ, Using
Molecular Genetic Techniques, for the Involvement of
Novel Genes

PRINCIPAL INVESTIGATOR: Teresa L. Mastracci
Irene L. Andrulis, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai Hospital
Toronto, Ontario, Canada M5G 1X5

REPORT DATE: June 2003

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031112 085

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2003	3. REPORT TYPE AND DATES COVERED Annual Summary (20 May 02 - 19 May 03)	
4. TITLE AND SUBTITLE Investigation of Lobular Carcinoma In Situ, Using Molecular Genetic Techniques, for the Involvement of Novel Genes			5. FUNDING NUMBERS DAMD17-02-1-0498	
6. AUTHOR(S) Teresa L. Mastracci Irene L. Andrulis, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai Hospital Toronto, Ontario, Canada M5G 1X5 E-Mail: teresam@mshri.on.ca			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) <p>Atypical lobular hyperplasia (ALH) and lobular carcinoma <i>in situ</i> (LCIS), i.e. lobular neoplasia, are lesions of significance in terms of implication of risk to the patient in the development of invasive carcinoma. A strong correlation between the lobular histological type and inactivation of E-cadherin, a protein involved in cell adhesion, has been reported. As well, mutations in the E-cadherin gene have been reported in invasive lobular carcinoma (ILC) and LCIS with adjacent ILC. The purpose of our study is to investigate lobular neoplastic lesions, lacking any adjacent invasive carcinoma, for alterations in and expression of known and novel genes/proteins with the goal of characterizing a molecular genetic profile for lobular neoplasia. We have accrued 23 cases of which there are 14 ALH lesions and 14 LCIS lesions. All cases able to be evaluated are negative for E-cadherin and beta-catenin protein expression by immunohistochemistry. The mutation analysis has been completed for thirteen lesions and to date alterations in the E-cadherin gene have only been characterized in LCIS. All ALH lesions screened to date show inactivation of E-cadherin but harbor no alterations. Studies are in progress to evaluate loss of heterozygosity at chromosome 16q, E-cadherin promoter methylation, and p120-catenin protein expression. The completion of these analyses will provide insight into the molecular genetic profile for lobular neoplasia.</p>				
14. SUBJECT TERMS Lobular carcinoma in situ, genetic profiling, Chromosomal CGH, CGH Microarray, Immunohistochemistry, E-cadherin				15. NUMBER OF PAGES 7
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	
Key Research Accomplishments.....	4
Reportable Outcomes.....	5
Conclusions.....	5
References.....	6
Appendices.....	7

Introduction

Tumor development from an early lesion through to invasive disease is not a clearly defined progression in the breast. A continuum can be hypothesized for breast lesions of the lobular histological type, from hyperplasia through *in situ* carcinoma to invasive breast carcinoma (IBC). However, discovering the specific molecular genetic events that mark the transition from an early lobular lesion to an invasive tumor is necessary to both support and subsequently understand this potential lobular progression.

Lobular neoplasia is a histological classification that includes atypical lobular hyperplasia (ALH) and lobular carcinoma *in situ* (LCIS).¹ Both ALH and LCIS are found incidentally during breast tissue biopsy due to their inability to be detected by palpation or mammography. Histologically there is a proliferative gradation from ALH to LCIS that is also reflected in the relative risk to the patient in the development of IBC. A finding of ALH imply a four to five fold increased risk of subsequent carcinoma in either breast, and a finding of LCIS implies an eight to ten fold increased risk to the patient.²⁻⁴

A strong correlation between the lobular histological type and inactivation of the cell adhesion protein epithelial(E)-cadherin has been reported.⁵⁻¹¹ As well, mutations in the E-cadherin gene have been found in invasive lobular carcinoma (ILC) and LCIS with adjacent ILC.⁵⁻¹¹ Our studies look to investigate both ALH and LCIS lesions, lacking any adjacent invasive carcinoma, for alterations in and expression of known and novel genes/proteins with the goal of characterizing a molecular genetic profile for lobular neoplasia.

Key Research Accomplishments

Since the inception of the study, the type of lesion being investigated has been expanded to include both types of lobular neoplastic lesions, i.e. ALH and LCIS. Tasks proposed in the original Statement of Work that looked solely to investigate LCIS lesions will now also be carried out on the accrued ALH lesions.

Task 1: Tissue Accrual

We have expanded the criteria for cases included in the study to include ALH, LCIS, or both ALH and LCIS. The original collection has been re-reviewed to identify all the lobular neoplastic lesions in each case. The number of cases in the study is currently at 23, including 14 ALH lesions and 14 LCIS lesions (with five cases housing both ALH and LCIS). All cases in the collection are formalin-fixed, paraffin-embedded breast tumor blocks containing lobular neoplastic lesions lacking adjacent invasive carcinoma. The accrual of cases remains ongoing. See appendix 1 for the detailed description of the current collection.

Task 2: Completion of the Analysis of E-cadherin in LCIS

The analysis has been completed for alterations in the E-cadherin gene in the original cases. As new cases are added to the collection, mutation analysis is being completed. A list of alterations characterized to date has been appended (appendix 1).

Task 3: Analysis of LCIS by Chromosomal Comparative Genome Hybridization (CGH)

The analysis of ALH and LCIS lesions by chromosomal CGH has not yet begun.

Task 4: Analysis of LCIS by CGH Microarray

In our laboratory, a CGH microarray protocol is currently being optimized and evaluated for accuracy and efficiency. Until this technique has been validated, the analysis of our lobular neoplastic lesions by CGH microarray will not commence.

Task 5: Analysis of LCIS by Immunohistochemistry (IHC)

As new cases are accrued, staining for protein expression by IHC is carried out. To date all cases have been stained for E-cadherin. Subsequently, staining for beta-catenin by IHC has also been optimized and completed on all cases currently in the collection. A scoring system has been developed in collaboration with Dr. Frances O'Malley for both E-cadherin and beta-catenin. A complete lack of E-cadherin and beta-catenin protein expression has been found in all cases of ALH and LCIS evaluated by IHC (appendix 1). Each lesion contains an adjacent internal positive control. As well, we have included a case of DCIS as a positive control for all IHC experiments. Currently, optimization of the p120-catenin antibody for IHC is in progress.

Additional work: Evaluation of methods of inactivation of E-cadherin in lobular neoplasia.

The results from our studies to date have suggested that in lobular neoplastic lesions E-cadherin may be inactivated by means other than the presence of mutation(s). To address this, other methods of E-cadherin inactivation, namely loss of heterozygosity (LOH) and E-cadherin promoter methylation, are being evaluated.

LOH analysis of chromosome 16q, which houses the E-cadherin gene, is being determined with the use of five microsatellite markers. The markers are located at 16q22.1/16q22.2 and fall upstream (D16S503, D16S496), downstream (D16S752, D16S3095) and within the E-cadherin gene (D16S421). This analysis has been completed for the original cases, and as new cases are added to the collection the LOH status for each lesion will be determined. The LOH results to date have been compiled in appendix 1.

The assessment of E-cadherin promoter methylation has also been proposed to be carried out on our lobular neoplastic lesions. Optimization of a methylation specific PCR protocol is in progress.

Reportable Outcomes

1. "E-cadherin alterations in lobular neoplasia". Manuscript is in preparation.
2. "Characterization of a molecular genetic profile for lobular neoplasia". Proceeding of the American Association of Cancer Research (1st Edition), volume 44, 2003.
3. "Characterization of a molecular genetic profile for lobular neoplasia". Department of Laboratory Medicine and Pathobiology Graduate Student Research Day, University of Toronto, March 2003.
4. "Analysis of E-cadherin in Lobular Carcinoma *in situ*". Proceedings of the American Association of Cancer Research, volume 43, 2002.
5. "Profiling Lobular Neoplasia". Center for Cancer Genetics Seminar Series, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, March 2002.
6. "Analysis of E-cadherin in Lobular Neoplasia". Department of Laboratory Medicine and Pathobiology Graduate Student Research Day, University of Toronto, March 2002.
7. "Analysis of E-cadherin in Lobular Neoplasia". Divisional Seminar Series, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, February 2002.

Conclusions

Cases lacking both expression of E-cadherin and gene alterations suggest that another mechanism, involved at the stage of hyperplasia, is causing the lack of protein expression. In light of these findings, studies are in progress to evaluate other mechanisms of gene silencing i.e. LOH and promoter methylation, as well as the expression status of proteins associated with E-cadherin. The completion of these analyses will provide insight into the molecular genetic profile for lobular neoplasia.

References

1. Lishman SC, Lakhani SR: Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology. *Histopathology* 1999, 35:195-200.
2. Page DL, Dupont WD, Rogers LW, Rados MS: Atypical hyperplastic lesions of the female breast. A long-term follow-up study. *Cancer* 1985, 55:2698-708.
3. Page DL, Kidd TE, Jr., Dupont WD, Simpson JF, Rogers LW: Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. *Hum Pathol* 1991, 22:1232-9.
4. Andersen JA: Lobular carcinoma in situ. A long-term follow-up in 52 cases. *Acta Pathol Microbiol Scand [A]* 1974, 82:519-33.
5. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene* 1996, 13:1919-25.
6. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A: Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. *Am J Pathol* 1993, 142:987-93.
7. Rieger-Christ KM, Pezza JA, Dugan JM, Braasch JW, Hughes KS, Summerhayes IC: Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. *Mol Pathol* 2001, 54:91-7.
8. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F: E-cadherin is a invasion/invasion suppressor gene mutated in human lobular breast cancers. *Embo J* 1995, 14:6107-15.
9. Huiping C, Sigurgeirsdottir JR, Jonasson JG, Eiriksdottir G, Johannsdottir JT, Egilsson V, Ingvarsson S: Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. *Br J Cancer* 1999, 81:1103-10.
10. Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van Roy F, Cornelisse CJ, Peterse JL, van de Vijver MJ: E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br J Cancer* 1997, 76:1131-3.
11. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol* 1997, 183:404-11.

Appendix 1: Summary of results from Case Accrual, E-cadherin Mutation Analysis, Immunohistochemistry, and LOH Analysis.

Case Code	Case Accrual		Mutation Analysis				Immunohistochemistry				LOH
	Original Study	Pathology	Alteration	Exon	bp	Effect	E-cadherin IHC	Internal Control	Beta-catenin IHC	Internal Control	LOH
A1	Yes	ALH	none				-	+	-	+	No
A2(L1)	Yes	ALH	none				-	+	-	+	No
A3(L3)		ALH	IP				-	+	-	+	IP
A4(L5)		ALH	IP				-	+	-	+	IP
A5	Yes	ALH	none				-	+	-	+	No
A6	Yes	ALH	none				N/A	N/A	N/A	N/A	N/A
A7	Yes	ALH	IP				-	+	-	+	No
A8		ALH	IP				-	+	-	+	IP
A9		ALH	none				-	+	-	+	IP
A10		ALH	IP				-	+	-	+	IP
A11(L12)		ALH	IP				-	+	-	+	IP
A12		ALH	IP				-	+	-	+	IP
A13		ALH	IP				-	+	-	+	IP
A14(L14)		ALH	IP				-	+	-	+	IP
L1(A2)	Yes	LCIS	GCC - ACC	7	856	Ala → Thr	-	+	-	+	Yes
			CAC - CGC	3	362	His → Arg	-				
L2	Yes	LCIS	CAT - TAT	3	274	His → Tyr	-	+	-	+	No
L3(A3)	Yes	LCIS	GCC - ACC	13	2125	Ala → Thr	-	+	-	+	MSI
L4	Yes	LCIS	11bp deletion	10	1417-1427	Frameshift, Stop	-	+	-	+	No
L5(A4)	Yes	LCIS	GTG - ATG	10	1459	Val → Met	-	+	-	+	No
L6	Yes	LCIS	AGC - AAC	11	1676	Ser → Asn	-	+	-	+	MSI
L7	Yes	LCIS	GGT - GAT	3	185	Gly → Asp	-	+	-	+	Yes
L8	Yes	LCIS	2 bp deletion	9	1309-1310	Frameshift, Stop	-	+	N/A	N/A	No
L9		LCIS	IP				-	+	-	+	N/A
L10		LCIS	IP				-	+	-	+	No
L11		LCIS	IP				N/A	N/A	N/A	N/A	No
L12(A11)		LCIS	IP				-	+	-	+	IP
L13		LCIS	IP				-	+	-	+	IP
L14(A14)		LCIS	IP				-	+	-	+	IP
Positive	Yes	DCIS	none				+	+	+	+	N/A

(ALH) atypical lobular hyperplasia; (LCIS) lobular carcinoma *in situ*; (DCIS) ductal carcinoma *in situ*; (bp) base pair; (-) negative protein expression; (+) positive protein expression; (N/A) tissue not available for experiment; (IP) in progress.